• Users Online: 12
  • Print this page
  • Email this page
REVIEW
Year : 2021  |  Volume : 1  |  Issue : 4  |  Page : 139-142

Managing patients with inflammatory bowel disease during the COVID-19 pandemic


Institute of Gastroenterology, Hepatobiliary Science and Transplantation, SRM Institutes for Medical Science, Chennai, Tamil Nadu, India

Correspondence Address:
Balakrishnan S Ramakrishna
Institute of Gastroenterology, Hepatobiliary Science and Transplantation, SRM Institutes for Medical Science, Vadapalani, Chennai - 600 026, Tamil Nadu
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ghep.ghep_40_21

Rights and Permissions

The coronavirus disease 2019 pandemic has paralyzed the world now for 20 months. SARS-CoV-2 infection appears to result in a number of inflammatory, thrombogenic, and immune events in susceptible individuals. Patients with inflammatory bowel disease (IBD) are on chronic immunosuppressive medication. Furthermore, they have relapses of disease that requires intensification of their immunosuppressive treatment. Our understanding of the management of such patients during a viral pandemic has significantly improved due to the scientific exchanges that have taken place, through print publication and virtual sharing of experiences among IBD caregivers. This brief review provides an overview of the basic immunology of SARS-CoV-2 infection, how it impacts patients with IBD and current guidelines on managing therapy for IBD patients during a pandemic.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed60    
    Printed2    
    Emailed0    
    PDF Downloaded6    
    Comments [Add]    

Recommend this journal